@tarzanofcali's TRT gains claims need context
Quick answer
The creator describes four months of testosterone replacement therapy with a recent dose adjustment for trough-level drops, consistent with standard cypionate or enanthate pharmacokinetics. His reported benefits including mood improvement, energy, facial hair development, and muscle response are clinically plausible outcomes for a hypogonadal patient in the early months of treatment. Claims of height gain and three shoe sizes of foot growth at age 26 are not supported by established endocrine physiology and warrant skepticism without imaging or provider confirmation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @tarzanofcali actually say?
The creator describes four months on TRT and lists some genuinely striking changes: improved mood, sleep, and energy; first-ever facial hair growth; a shoe size jump from 7 to 10; growing half an inch in height at 26; and "insane" pumps and vascularity after just two weeks back in the gym. He also mentions his dosage was recently increased because testosterone levels were dropping toward the end of his injection cycle. He is 26 years old, and this appears to be ongoing treatment, not a completed one.
The tone is enthusiastic and personal. He is not telling anyone to start TRT, but at 22.2K views with hashtags like "teenagers" and "puberty," the implied audience is young men wondering if they should.
Does the science back this up?
Mostly yes on the mood, sleep, energy, and muscle-pump claims. On the height and shoe size claims, the science gets complicated fast, and not in a flattering way for the narrative.
Testosterone's effects on mood and energy in hypogonadal men are well-documented. A 2016 randomized trial by Snyder et al. in NEJM showed significant improvements in sexual function, mood, and walking ability in men with low testosterone. The gym performance and vascularity claims are also plausible. Testosterone increases erythropoiesis and muscle protein synthesis even over short periods, so two weeks of training on a therapeutic dose producing noticeable pumps is not far-fetched.
The facial hair claim is interesting. Testosterone does drive beard development through DHT conversion. If his pre-treatment levels were genuinely low during late adolescence or early adulthood, delayed secondary sex characteristic development is a recognized clinical finding. That part checks out.
What did they get wrong (or right)?
The height and shoe size claims are where this gets medically murky. Growing half an inch and jumping three shoe sizes at 26 on TRT is not a documented pharmacological effect of testosterone replacement in adults with closed growth plates. Epiphyseal plate closure typically occurs by the early-to-mid 20s. A 2020 review by Eastell et al. in Nature Reviews Endocrinology confirms that once growth plates are fused, exogenous androgens do not produce longitudinal bone growth.
Could some residual growth have occurred? Theoretically, if his plates were not fully closed due to prior hypogonadism delaying skeletal maturation, yes. But that is a clinical finding requiring imaging confirmation, not a casual "I grew half an inch" moment. The shoe size jump of three full sizes is even harder to explain physiologically. Ligament laxity changes or weight gain affecting foot spread are possible, but a 3-size jump is dramatic and lacks a credible mechanism at this age.
He got the acne right, at least. Acne from TRT is real and common, driven by DHT and sebum production.
What should you actually know?
If you are a young man watching this and thinking TRT sounds like a growth hack, that framing is dangerous. TRT is a clinical treatment for diagnosed hypogonadism, not a performance supplement. The creator appears to have a legitimate diagnosis, and the mood, energy, and muscle response he describes are consistent with treating an actual deficiency.
But the height and shoe size gains should not be the selling point anyone takes home. If a 26-year-old without prior hypogonadism-related delayed development starts TRT expecting to grow taller, that is not going to happen. Worse, exogenous testosterone in young men with normal levels suppresses natural production via the HPG axis and can impair fertility, sometimes for years. A 2021 paper by Kovac et al. in Fertility and Sterility found that up to 25% of men on exogenous testosterone had persistent spermatogenic suppression six months after stopping.
The dosage increase he mentions because levels were dropping at cycle's end is a real pharmacokinetic issue with testosterone cypionate and enanthate. That is a legitimate clinical conversation to have with a prescriber, not a red flag on its own.
- TRT for diagnosed hypogonadism has real, evidence-backed benefits for mood, energy, and body composition.
- Height and shoe size changes at 26 are not expected TRT outcomes and should not influence anyone's treatment decision.
- Acne is a real and common side effect, not a sign something is wrong with the dose.
- Young men without a diagnosis should not read this video as an endorsement to seek TRT for performance reasons.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @tarzanofcali's TRT gains claims need context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@tarzanofcali's TRT gains claims need context is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes four months of testosterone replacement therapy with a recent dose adjustment for trough-level drops, consistent with standard cypionate or enanthate pharmacokinetics.
FormBlends verdict
The creator describes four months of testosterone replacement therapy with a recent dose adjustment for trough-level drops, consistent with standard cypionate or enanthate pharmacokinetics. His reported benefits including mood improvement, energy, facial hair development, and muscle response are clinically plausible outcomes for a hypogonadal patient in the early months of treatment. Claims of height gain and three shoe sizes of foot growth at age 26 are not supported by established endocrine physiology and warrant skepticism without imaging or provider confirmation.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes four months of testosterone replacement therapy with a recent dose adjustment for trough-level drops, consistent with standard cypionate or enanthate pharmacokinetics. His reported benefits including mood improvement, energy, facial hair development, and muscle response are clinically plausible outcomes for a hypogonadal patient in the early months of treatment. Claims of height gain and three shoe sizes of foot growth at age 26 are not supported by established endocrine physiology and warrant skepticism without imaging or provider confirmation.
- Snyder et al. (2016, NEJM) confirmed mood, energy, and physical function improvements in hypogonadal men on TRT in a randomized controlled trial.
- Testosterone drives DHT-dependent facial hair growth, making delayed beard development a legitimate clinical finding in men with true hypogonadism.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Snyder et al. (2016, NEJM) confirmed mood, energy, and physical function improvements in hypogonadal men on TRT in a randomized controlled trial.
- Testosterone drives DHT-dependent facial hair growth, making delayed beard development a legitimate clinical finding in men with true hypogonadism.
- Growth plates are typically fused by the mid-20s; exogenous testosterone does not produce height gains in adults with closed epiphyses, per Eastell et al. (2020).
- A 3-shoe-size increase at age 26 has no established physiological mechanism linked to testosterone replacement and should not be treated as an expected outcome.
- Kovac et al. (2021, Fertility and Sterility) found up to 25% of men on exogenous testosterone had persistent spermatogenic suppression six months after stopping, a risk young men should understand.
- Acne onset or worsening during TRT is a real and common side effect driven by DHT-stimulated sebum production, not a dosing error.
- TRT is a clinical treatment for diagnosed hypogonadism. Young men with normal testosterone levels will not replicate these outcomes and face real hormonal suppression risks.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
ezequieldecastilla · TikTok creator
22.2K views on this video
Gains are getting stooopid #lowt #trt #testosterone #menshealth #teenagers #college #acne #puberty #lowtestosterone #bulkingseason
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by ezequieldecastilla, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.